Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

Nikhil Prasad  Fact checked by:Thailand Medical News Team Jan 04, 2024  1 month, 2 weeks, 6 days, 14 hours, 30 minutes ago

Pharma News: Pfizer Acquires Cancer Drug Company Seagen For 43 Billion US Dollars In Anticipation Of The Rise In Turbo Cancers!

facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
Pharma News: Pfizer Acquires Cancer Drug Company Seagen For 43 Billion US Dollars In Anticipation Of The Rise In Turbo Cancers!
Nikhil Prasad  Fact checked by:Thailand Medical News Team Jan 04, 2024  1 month, 2 weeks, 6 days, 14 hours, 30 minutes ago
Pharma News: In an unexpected and controversial move, pharmaceutical behemoth Pfizer has plunged into the realm of oncology with the acquisition of Seagen, a small drug company specializing in the treatment of "turbo cancers."

This staggering US$43 billion deal has left many perplexed, especially considering Pfizer's already robust profits from its mRNA vaccine. This Pharma News report delves into the intricacies of this acquisition, exploring the motives behind it and shedding light on the escalating concerns surrounding turbo cancers linked to mRNA vaccines.
Turbo Cancers Unleashed by mRNA Vaccines?
Crucially, Pfizer's COVID-19 mRNA vaccine, along with Moderna's counterpart, has been implicated in the surge of turbo cancers - an unprecedented phenomenon in medical history. However to date there is no real documented evidence that the COVID-19 mRNA vaccines are causing cancers as accepted by the scientific community. Numerous medical articles and reports have documented various types of turbo cancers emerging post-vaccination, including lymphoma, brain cancers, breast cancer, colon cancer, and lung cancer. Some claim that this alarming trend has perhaps compelled Pfizer to take decisive action.
It should however be noted that COVID-19 infections itself can also give rise to cancers or help in the faster progression of cancers.,-leading-to-lung-fibrosis-and-lung-cancer-erlotinib-helps
Pfizer's Strategic Move: The Seagen Acquisition
With the acquisition of Seagen, Pfizer not only cements its position as the global leader in oncology but also gains the capability to treat seven out of the top ten turbo cancers. This strategic move signifies Pfizer's commitment to addressing any unintended consequences arising from its mRNA vaccine while simultaneously positioning itself as a major player in managing these complex conditions.
However, beneath the surface, there are deeper, more ominous details at play.
Sinister Undercurrents: Decoding Pfizer CEO Albert Bourla's Vision
Insights from Pfizer CEO Albert Bourla's recent media interviews provide a glimpse into the motivations driving this acquisition. Bourla envisions a future where turbo cancers afflict 33 to 60% of the population, affecting entire families.
Describing the new cancer treatments as "missiles" targeting "most" turbo cancers, Bourla emphasizes Pfizer's unprecedented scale of production, echoing the magnitude of its mRNA vaccine manufacturing. This prompts critical questions about the future trajectory of turbo cancers and the undisclosed information that Bourla and his team may possess. Notably, financial analysts suggest that Pfizer might take a decade to recoup its investment, adding complexity to the narrative.
In a separate dimension of this transformative deal, Pfizer CEO Albert Bourla emphasizes the potential of Seagen's cancer therapy to be delivered globally "at a scale that has not been seen before." Seagen specializes in antibody-drug conjugates (ADCs), a cutting-edge technology designed to annihilate cancer cells while sparing healthy ones. Bourla draws parallels between ADCs and mRNA technology, emphasizing their potential as "turbo-charged guided missiles" in the battle against cancer.
Seagen's portfolio, including the widely successful Adcetris, which treats lymph system cancers, positions Pfizer to treat seven out of the top ten turbo cancers. Bourla projects significant growth, estimating Seagen's contribution to Pfizer's revenue to exceed $10 billion by 2030. This strategic move aligns with Pfizer's anticipation of declining COVID-related sales, redirecting focus towards oncology, considered the industry's biggest growth market.
The Future Landscape of Turbo Cancers: Unraveling the Mystery
The need for Pfizer to produce cancer treatments on an unparalleled scale raises concerns about the projected exponential growth of turbo cancers worldwide. Critics argue that the BioNTech-Pfizer vaccines, backed by the Bill & Melinda Gates Foundation, may have far-reaching consequences that mainstream media is suppressing. Governments globally are now sounding alarms about an impending surge in turbo cancers following widespread vaccine rollouts, necessitating urgent attention and thorough investigation into this medical catastrophe.
Conclusion: Navigating the Unknown Terrain
As Pfizer places a $43 billion bet on turbo cancers, the precise motives behind this acquisition remain shrouded in uncertainty. The rise of turbo cancers post-mRNA vaccinations is an urgent concern demanding transparent investigation and prioritization of the well-being of those affected. Governments, medical professionals, and the public must collaborate to unravel the complexities surrounding this issue.
Challenges Ahead: Anticipating Regulatory Scrutiny
As Pfizer aims to complete the transaction in 2024, potential regulatory challenges loom due to the acquisition's size. Bourla however expresses confidence in overcoming antitrust hurdles, asserting the company's readiness for any challenges. Pfizer has strong ties with filthy and corrupted American and European politicians and is also close to filth like Bill Gates and Klaus Schwab.
Cancer, responsible for nearly 10 million deaths in 2020 according to the World Health Organization, remains a global concern, with the American Cancer Society predicting a significant increase in new cases and deaths by 2040.
Bourla underscores the far-reaching impact of cancer, affecting not only patients but their families as well. With this acquisition, Pfizer envisions making a substantial difference in tackling the global burden of cancer. As the pharmaceutical giant navigates uncharted territories, the world watches closely, anticipating breakthroughs, challenges, and revelations in the unfolding narrative of Pfizer's $43 billion gamble on turbo cancers.
For the latest Pharma News, keep on logging to Thailand Medical News.
Read Also:


Jun 10, 2023  9 months ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
Sep 08, 2022  1 year ago
Source- Medical News - COVID-19 Research - Impaired Pain Modulation
Aug 04, 2022  2 years ago
Source: Medical News - SARS-CoV-2 & Cancer
Aug 13, 2020  4 years ago
Source: Supplements For COVID-19